How strong is retatrutide's evidence?

By the standards of this library, unusually strong. Randomised controlled trials in NEJM and the Lancet, and a Phase 3 programme of over 5,800 participants.

Why is there no PubChem entry?

Not clear, and it is unusual for a compound at this stage. The clinical record is strong while the chemical record is not.

Retatrutide in the Published Literature

The short answer

Retatrutide's literature is small but unusually strong: the discovery paper in Cell Metabolism, Phase 2 results in the New England Journal of Medicine and the Lancet, and a Phase 3 programme enrolling more than 5,800 participants reported through Lilly and ClinicalTrials.gov.

Key facts

Discovery: Coskun, Cell Metab 2022 (PMID 35985340)
Phase 2 obesity: Jastreboff, NEJM 2023 (PMID 37366315)
Phase 2 T2D: Rosenstock, Lancet 2023 (PMID 37385280)
Phase 3 enrolment: More than 5,800
Evidence quality: High (randomised, controlled)
Chemical database entry: None findable

An unusual profile for this library

Most compounds here have a large preclinical literature and no controlled human data. Retatrutide has the opposite: relatively few papers, but among them randomised controlled trials published in the New England Journal of Medicine and the Lancet, and a Phase 3 programme of more than 5,800 participants. On evidence quality it is not comparable to anything else in this catalogue.

The three foundational papers

Coskun and colleagues in Cell Metabolism, September 2022, for the discovery and pharmacology. Jastreboff and colleagues in the New England Journal of Medicine, 2023, for Phase 2 in obesity. Rosenstock and colleagues in the Lancet, 2023, for Phase 2 in type 2 diabetes. Almost everything else cites one of these.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £49.99

Where the Phase 3 data lives

Topline results have been reported through Eli Lilly investor releases, with trials registered on ClinicalTrials.gov. Peer-reviewed publication follows database posting, so for the most recent readouts the investor release is currently the primary accessible source, which is a weaker form of reporting than a full paper.

The gap that is odd

For a compound with this much clinical evidence, retatrutide has no findable PubChem entry. Searches under the name, the development code and the reported CAS all return nothing. The clinical literature is stronger than almost anything else here while the chemical record is weaker, an inversion worth knowing about when checking a certificate of analysis.

How to search it

PubMed under retatrutide and LY3437943. ClinicalTrials.gov for the TRIUMPH registrations, searched directly rather than through secondary sources, because trial status changes. Lilly's investor releases for topline data ahead of publication. Each covers something the others do not.

What none of it establishes

That retatrutide is available or approved. It is investigational everywhere, and the strength of the trial evidence does not change its regulatory position. Research material supplied under this name is not the trial compound.

Frequently asked questions

How strong is retatrutide's evidence?: By the standards of this library, unusually strong. Randomised controlled trials in NEJM and the Lancet, and a Phase 3 programme of over 5,800 participants.
Where are the Phase 3 results published?: Topline data through Eli Lilly investor releases, with trials registered on ClinicalTrials.gov. Peer-reviewed publication follows.
Why is there no PubChem entry?: Not clear, and it is unusual for a compound at this stage. The clinical record is strong while the chemical record is not.

Extended research context

The Retatrutide Research deep dive

Deep dive: how the triple-agonist scaffold was engineered

Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance. This is the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.

The TRIUMPH Phase 3 programme in context

TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator (FDA, EMA, or MHRA) has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.

How retatrutide differs from tirzepatide and semaglutide at the mechanism level

Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press, but the pharmacology is more nuanced than the label implies.

Research applications

▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
▸Reference material for teaching incretin pharmacology in university-level courses

Handling checklist

✓Store lyophilised vials at −20 °C; protect from light and humidity
✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
✓Once reconstituted, store at 2–8 °C and use within 28 days
✓Verify batch CoA: HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
✓Do not administer to humans or animals. Research use only

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing retatrutide with tirzepatide in supplier catalogues

Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.

✗ Using tap or filtered water for reconstitution

Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water, never lab DI water.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum